Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

“This drug takes the first new approach to schizophrenia treatment in decades,” Farchione continued. “This approval offers a ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.

The new drug, Bristol Myers Squibb’s Cobenfy, targets a different area of the brain than traditional antipsychotic drugs to relieve symptoms like delusions without causing patients to gain ...

High MMP9 was associated with poor antipsychotic treatment response and changes in white matter density among patients with schizophrenia.

Neurocrine Biosciences said it plans to halt development of luvadaxistat for cognitive impairment associated with ...

The deaths of a couple who were killed by their son could have been avoided if he had been prescribed antipsychotic ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...